The SMART-7 Study: A Prospective, Post-Authorisation Non-Interventional Study on Room Temperature Stable Recombinant Activated Factor VII (VII25) in Patients with Haemophilia A or B with Inhibitors

被引：0
|
作者：
Benson, G. [1 ]
El Fegoun, S. Benchikh [2 ]
Chambost, H. [3 ]
Demartis, F. [4 ]
Zak, M. [5 ]
Kavakli, K. [6 ]
机构：
[1] Belfast City Hosp, Northern Ireland Haemophilia Comprehens Care Ctr, Belfast BT9 7AD, Antrim, North Ireland
[2] Novo Nordisk Healthcare AG, BioPharm Global Med Affairs, Zurich, Switzerland
[3] Hop Enfants La Timone, Ctr Hemophiles, Marseille, France
[4] AOUC Azienda Osped Univ, Florence, Italy
[5] Novo Nordisk AS, Med & Sci Haemophilia R&D Portfolio, Soborg, Denmark
[6] Ege Univ, Childrens Hosp, Dept Haematol, Izmir, Turkey
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P057
引用
收藏
页码：54 / 55
页数：2
相关论文
共 14 条
  • [1] Safety of room temperature stable recombinant activated factor VII (VII25) in patients with haemophilia A or B with inhibitors: results from the prospective, non-interventional smart-7 study
    Kavakli, K.
    Chambost, H.
    Demartis, F.
    Sommer, L.
    Zak, M.
    Benson, G.
    HAEMOPHILIA, 2016, 22 : 52 - 52
  • [2] Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia a or B with Inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-Interventional SMART-7™ Study
    Benson, Gary
    Chambost, Herve
    Demartis, Francesco
    El Fegoun, Soraya Benchikh
    Cepo, Katarina
    Sommer, Lene
    Kavakli, Kaan
    BLOOD, 2016, 128 (22)
  • [3] Bleeding Characteristics Of Patients With Congenital Haemophilia And Inhibitors: Data From A Postmarketing Study Of Recombinant Activated Factor VII (SMART-7)
    Kavakli, K.
    Demartis, F.
    Benson, G.
    Cepo, K.
    Chambost, H.
    Batorova, A.
    Zak, M.
    HAEMOPHILIA, 2017, 23 : 91 - 91
  • [4] Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders
    Birschmann, I.
    Klamroth, R.
    Eichler, H.
    Schenk, J.
    Kirchmaier, C. M.
    Halimeh, S.
    HAEMOPHILIA, 2013, 19 (05) : 679 - 685
  • [5] Interim results from the prospective observational study on Novoseven® room temperature stable (VII25) in patients with hemophilia A or B
    Kavakli, K.
    Arkhammar, P.
    Benson, G.
    Chambost, H.
    De Martis, F.
    Rosholm, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 63 - 64
  • [6] Bleeding characteristics of patients with congenital hemophilia and inhibitors: Data from a postmarketing study of recombinant activated factor VII (SMART-7)
    Demartis, Francesco
    Benson, Gary
    Batorova, Angelika
    Cepo, Katarina
    Zak, Marek
    Chambost, Herve
    HAEMOPHILIA, 2016, 22 : 68 - 68
  • [7] Home treatment of haemarthrosis with activated recombinant factor VII (RFVIIA) in haemophilia A and B patients with inhibitors: a prospective observational study
    Belhani, M. F.
    Khalifa, H. Hadj
    Wali, Y. A. S.
    Alzoebie, A.
    Saad, H. A.
    El Feegoun, S. Benchikh
    HAEMOPHILIA, 2013, 19 : 43 - 44
  • [8] Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study
    Kavakli, K.
    Demartis, F.
    Karimi, M.
    Eshghi, P.
    Neme, D.
    Chambost, H.
    Sommer, L.
    Zak, M.
    Benson, G.
    HAEMOPHILIA, 2017, 23 (04) : 575 - 582
  • [9] Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia
    Morfini, M.
    Bjerre, J.
    HAEMOPHILIA, 2011, 17 (06) : 860 - 866
  • [10] Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study
    Rivard, G. E.
    Rothschild, C.
    Toll, T.
    Achilles, K.
    HAEMOPHILIA, 2013, 19 (03) : 449 - 455
12